US pulls funding from global vaccines group, saying it has 'ignored the science'
U.S. Health Secretary Robert F. Kennedy Jr. said the country is pulling its support from the vaccines alliance Gavi, saying the organization has 'ignored the science' and 'lost the public trust.'
A video of Kennedy's speech was shown to participants at a Gavi meeting in Brussels on Wednesday, where the vaccines group was hoping to raise at least $9 billion for the next five years.
Gavi is a public-private partnership including WHO, UNICEF, the Gates Foundation and the World Bank. It has paid for more than 1 billion children to be vaccinated through routine immunization programs, saving an estimated 18 million lives. The U.S. has long been one of its biggest supporters; before Trump's re-election, the country had pledged $1 billion through 2030.
Kennedy called on Gavi 'to re-earn the public trust and to justify the $8 billion America has provided in funding since 2001,' saying officials must 'consider the best science available, even when that science contradicts established paradigms.' Kennedy said until that happens, the U.S. won't contribute further to Gavi.
Kennedy, a longtime vaccine skeptic, said he and President Trump were concerned about how Gavi and the World Health Organization partnered together during the COVID-19 pandemic to work with social media companies 'to silence dissenting views, to stifle free speech and legitimate questions' during a time when many people had questions about vaccine safety.
Kennedy said Gavi continues to make 'questionable recommendations,' like advising pregnant women to get immunized against COVID-19 and funding the roll-out of a vaccine against diphtheria, tetanus and pertussis in poorer countries.
WHO and other health authorities have recommended pregnant women get vaccinated against COVID-19, saying they are at higher risk of severe disease.
Kennedy said he has seen research that concluded that young girls vaccinated against diphtheria, tetanus and pertussis were more likely to die from all other causes than children who weren't immunized.
Gavi said in a statement Thursday that its 'utmost concern is the health and safety of children.' The organization said any decision it makes on vaccines to buy is done in accordance with recommendations issued by WHO's expert vaccine group.
'This ensures Gavi investments are grounded in the best available science and public health priorities,' it said. Gavi said scientists had reviewed all available data, including any studies that raised concerns, and that the diphtheria, tetanus and pertussis vaccine has 'played a key role in helping halve childhood mortality.'
The British government said Wednesday it would give 1.25 billion pounds ($1.7 billion) between 2026 and 2030 to Gavi. It said the money would help Gavi protect up to 500 million children in some of the world's poorest countries from diseases including meningitis, cholera and measles.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
World Health Organization is STILL siding with China over Covid's origins as report rules out lab leak
A group of experts investigating Covid origins on behalf of the World Health Organization revealed they still aren't sure how the pandemic began. At a press briefing Friday, chair of the group Marietjie Venter said most data supports the idea that Covid jumped to humans from animals. It's the same conclusion the WHO drew in 2021, when scientists said the virus likely spread from bats to human through another 'intermediary animal.' Venter said that after three years of investigating, the WHO group was unable to get necessary data to determine if Covid was the result of a lab leak, despite hundreds of requests for genetic sequences and biosecurity information to the Chinese government. She said: 'Therefore, this hypothesis could not be investigated or excluded. It was deemed to be very speculative, based on political opinions and not backed up by science.' She said there was no evidence to prove that Covid had been manipulated in a lab, nor was there any indication that the virus had been spreading before December 2019 anywhere outside of China. Venter claims the 27-member group did not reach a firm consensus on Covid's origins, as one member resigned earlier this week and three others asked for their names to be removed from the report. She said: 'Until more scientific data becomes available, the origins of how SARS-CoV-2 entered human populations will remain inconclusive.' The report comes after US authorities said earlier this month they had 'seized' Dr Anthony Fauci's old phone in search of answers about Covid's origin. FBI boss Kash Patel told Joe Rogan: 'We found it [the devices], and at least we can tell the American people we've been looking because it is of public importance to figure out, did that guy lie? 'Did he intentionally mislead the world and cause countless deaths?' The FBI and CIA have both asserted they think Covid most likely originated from the Wuhan Institute of Virology in Wuhan, China, which was conducting risky experiments on coronaviruses in the years leading up to the pandemic. Some of those experiments were funded by US taxpayer money through grants awarded by Dr Fauci's old department, the National Institute of Allergy and Infectious Diseases (NIAID). WHO Director-General Tedros Adhanom Ghebreyesus said it was a 'moral imperative' to determine how Covid began, noting that the virus killed at least 20 million people worldwide, wiped at least $10trillion from the global economy and upended the lives of billions. Last year, the AP found that the Chinese government froze meaningful domestic and international efforts to trace the virus' origins in the first weeks of the outbreak in 2020 and that WHO itself may have missed early opportunities to investigate how Covid began. President Donald Trump has long blamed the emergence of the coronavirus on a laboratory accident in China, while a U.S. intelligence analysis found there was insufficient evidence to prove the theory. Chinese officials have repeatedly dismissed the idea that the pandemic could have started in a lab, saying that the search for its origins should be conducted in other countries. Last September, researchers zeroed in on a short list of animals they think might have spread COVID-19 to humans, including racoon dogs, civet cats and bamboo rats. The German Federal Intelligence Service (BND) carried out a secret investigation into the origins of Covid nicknamed Project Saaremaa during the pandemic, sharing the findings with the US in December 2024. Investigators found unpublished dissertations from 2019 and 2020 that allegedly discussed the effects of coronaviruses on the human body. Additionally, uncovered materials revealed Chinese scientists had 'an unusually large amount of knowledge about the supposedly novel virus available at an unusually early stage.' Based on the materials BND agents found and analyzed, they used a 'Probability Index' to measure the reliability of information, which determined the lab-leak theory was 'probable' with an '80 to 95 percent' certainty. Robert Redfield, former CDC director when the pandemic erupted, also accused American and British health agencies of shutting down concerns over potential lab leaks. He previously told he is '100 percent' convinced Covid was the result of scientists becoming infected while carrying out high-risk experiments to boost the infectivity of bat viruses amid low biosecurity in Wuhan labs.
Telegraph
2 hours ago
- Telegraph
WHO: Lab leak cannot be ruled out as Covid source
The report said that the 'weight of available evidence' suggested a zoonotic spillover, but warned investigators could not 'conclude with certainty where and when this occurred'. The WHO has called for an independent review of what research was being carried out in laboratories near the wet market, including biosafety practices and the health of staff prior to the outbreak. Before the pandemic, WIV had collected more than 220 Sars-related coronaviruses, at least 100 of which were never made public. Members of staff were also photographed wearing inadequate levels of personal protective equipment while handling bats. US intelligence also discovered that three researchers at WIV had sought treatment at a hospital after falling ill with Covid-like symptoms in November 2019. In 2023, a US Senate committee inquiry concluded: 'The preponderance of circumstantial evidence supports an unintentional research-related incident.' WIV was stripped of United States government funding the same year after it was determined the laboratory had conducted dangerous experiments that increased the potency of coronaviruses before the pandemic. Dr Marietjie Venter, chairman of the Sago group said: 'Understanding the origins of SARS-CoV-2 and how it sparked a pandemic is needed to help prevent future pandemics, save lives and livelihoods, and reduce global suffering.'
NBC News
2 hours ago
- NBC News
By maintaining Obamacare pillar, Supreme Court hands win to HIV advocates
The Supreme Court on Friday granted the HIV-prevention field a historic win — yet with a major caveat — as it upheld a federally appointed health task force's authority to mandate no-cost insurance coverage of certain preventive interventions, but clarifying that the Health and Human Services secretary holds dominion over the panel. The 6-3 decision in Kennedy v. Braidwood Management, Inc. essentially leaves in place a popular pillar of the Affordable Care Act, which mandates that most insurers cover various task force-recommended preventive screenings, therapies and interventions, with no out-of-pocket costs imposed on patients. The case reached the high court after a group of Christian businesses in Texas objected to being compelled to cover a certain drug used for HIV prevention, known as PrEP, given their claims that it 'promotes homosexuality.' 'Since our efforts to address HIV in the U.S. are under attack on so many levels, preserving insurers' requirement to cover preventive services, including PrEP, will help ensure access to people who need it,' said Carl Schmid, executive director of the HIV + Hepatitis Policy Institute, a patient advocacy group in Washington, D.C. But the court clarified the scope of the task force's independence, thus potentially compromising its impact. Addressing concerns that the 16-member volunteer task force's power over insurers was unconstitutional, the justices asserted that the health secretary holds the authority to appoint and dismiss the panelists and to block their new recommendations from mandating insurance coverage. The secretary could also possibly direct the panel, including one stocked with his or her own hand-picked members, to revisit previous recommendations that have already gone into effect. Given the unpredictable nature and unconventional approach to health policy of the current health secretary, Robert F. Kennedy Jr., HIV advocates are concerned that he might undermine the task force's current or future endorsements of HIV-prevention medications, known as PrEP. The ruling 'is a victory in the sense that it leaves intact the requirement to cover task-force recommendations,' said attorney Richard Hughes, a partner with Epstein Becker Green in Washington, D.C., who represented a group of HIV advocacy organizations in submitting a friend-of-the-court brief in the casel. 'It was always going to be a double-edged sword, as the political accountability that salvaged its authority comes with the ability to alter its recommendations.' The U.S. has secured only a modest decline recently in HIV cases, and HIV advocates stand at a crossroads amid the Trump administration's dramatic withdrawal of support for their cause. Promisingly, the Food and Drug Administration last week approved a long-acting injectable form of PrEP, Yeztugo, made by Gilead Sciences. Injected every six months, Yeztugo overwhelmingly bested Truvada, a daily-pill form of PrEP also made by Gilead, at lowering HIV transmissions in clinical trials. But Yeztugo has debuted as the Trump administration is gutting the Centers for Disease Control and Prevention's HIV-prevention division and after it canceled scores of HIV-related research grants. HIV experts have warned that this upheaval could lead HIV to rise again. Kennedy v. Braidwood Management, Inc. The plaintiffs' initial religious-liberty complaint was ultimately dropped from the case. The court more narrowly considered the constitutionality of an ACA provision that lent effective authority to a longstanding volunteer medical task force to mandate no-cost insurance coverage to preventive interventions that the expert group rated highly, including PrEP. The plaintiffs argued that because the task force was not appointed by the president and confirmed by the Senate, granting it such power over insurance markets violated the Constitution's appointments clause. The justices grappled with the task force's balance of independence versus accountability. In particular, they sought to determine whether the task force members were appointed by the Senate-confirmed Health and Human Services secretary. In addition to PrEP, the task force has issued high scores, for example, to screening for lung cancer, diabetes, and HIV; treatment to help quit smoking; and behavioral counseling to prevent heart disease. Had the Supreme Court fully sided with the plaintiffs, insurers would have been free to drop such popular benefits or, at the very least, to impose related co-pays and other cost sharing. Writing for the majority, Justice Brett Kavanaugh found that the health secretary has the power 'to appoint Task Force members, and no statute restricts their removal.' He was joined by an ideological mix of colleagues, including Chief Justice John Roberts and Justice Amy Coney Barrett on the right, and Justices Sonia Sotomayor, Elena Kagan and Ketanji Brown Jackson on the left. Concerns and uncertainty about Kennedy HIV advocates expressed concern that Kennedy might undo the task force's recommendation for PrEP, or at the least deprioritize ensuring that Yeztugo receives a clear coverage mandate. Earlier this month, Kennedy dismissed the entire CDC Advisory Committee on Immunization Practices, or ACIP, and replaced them with his own hand-picked selections, including one notable anti-vaccine activist. At the first meeting of the newly formed committee this week, ACIP dropped recommendations for some flu vaccines over claims, widely debunked by researchers, that one ingredient in them is tied to autism. Mitchell Warren, executive director of the HIV advocacy nonprofit AVAC, expressed concern about 'what happened with the CDC ACIP this week, as it could be a harbinger of what a secretary of HHS can do to twist committees and task forces that should be composed of experts guided by science to ones that are guided by ideology and politics.' In an email to NBC News, Carmel Shachar, faculty director of the Health Law and Policy Clinic at Harvard Law School, characterized Kennedy's potential approach to overseeing the health task force as unpredictable. 'RFK has been skeptical of the medical approach to HIV/AIDS in the past, and that may color his attitude to revising PrEP guidance,' Shachar said. HHS did not immediately respond to a request for comment about the HIV advocates' concerns. In 2019, the health task force granted Truvada as PrEP a top rating. The drug was already widely covered by insurers. But under ACA rules, the task force's recommendation meant that by January 2021, insurance plans needed to cease imposing cost-sharing for the drug. The Centers for Medicare and Medicaid Services, or CMS, then clarified that insurers were also forbidden to impose cost sharing for the quarterly clinic visits and lab tests required for a PrEP prescription. A CDC study published in October found that about 200,000 people were using PrEP at any point in 2023. In 2019, the FDA approved another Gilead daily pill, Descovy, for use as PrEP. In late 2021, ViiV Healthcare's Apretude — an injection given every two months — was also green lit. The health task force gave top ratings to both of the newer forms of PrEP in 2023, which triggered a mandate for no-cost coverage to begin in January. A generic version of Truvada emerged in 2020 and now costs as little as $30 per month. The list prices of the three brand-name PrEP drugs range from about $2,200 to $2,350 a month. How the court's ruling could play out for HIV prevention Were Kennedy to appoint task force members who ultimately voided the PrEP coverage mandate, generic Truvada, at the very least, would still likely remain widely covered by insurance. But insurers would be free to demand cost-sharing for all forms of PrEP, including for required clinic visits and lab tests. And they could restrict access to the more expensive versions, including by imposing prior authorization requirements and higher cost sharing. Research suggests that even a small increase in monthly out-of-pocket costs for PrEP can depress its use and that those who accordingly forgo a prescription are especially likely to contract HIV. Johanna Mercier, Gilead's chief commercial officer, said even before the health task force's 2023 insurance mandate for Descovy went into effect in January, the drug's coverage was still pretty solid. Private insurers provided unrestricted coverage of Descovy for PrEP to 74% of commercially insured people, and 40% of prescriptions for the drug had no co-pay. After the mandate went into effect — including after CMS released a clarification on the PrEP-coverage mandate in October — those rates increased to 93% and 85%, respectively. This experience, Mercier said, has left the company optimistic that an increasing proportion of health plans will cover Yeztugo during the coming months. Health-policy experts are not certain whether the existing PrEP rating from the task force automatically applies to Yeztugo, or whether the drug will require its own rating to ensure coverage comes with no cost sharing. If Apretude's history is any guide, a requirement for Yeztugo to receive a specific rating could delay a no-cost insurance-coverage mandate for the drug from going into effect until January 2027 or 2028. It's also possible that CMS could release guidance clarifying that the existing mandate for PrEP coverage applies to Yeztugo, which would likely have a more immediate impact on coverage. However, Elizabeth Kaplan, director of health care access at Harvard's Health Law and Policy Clinic, said in an email that 'given this administration's and RFK's stated priorities,' the publication of a guidance on Yeztugo coverage by an HHS division 'appears unlikely.'
